Stem cell therapy market

Stem Cell Therapy Market, by Cell Source (Adult Stem Cells, Induced Pluripotent Stem Cells, Embryonic Stem Cells, and Others), by Application (Musculoskeletal Disorders, Wounds and Injuries, Cancer, Autoimmune Disorders, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Request Free Sample

Sep 2022
CMI2848
153 Pages
Excel & Pdf
Biotechnology

Summary

Stem cell therapy, also known as regenerative medicine, promotes the repair response of diseased, dysfunctional or injured tissue using stem cells or their derivatives. It is the next chapter in organ transplantation and uses cells instead of donor organs, which are limited in supply. Stem cells are cells with the potential to develop into many different types of cells in the body. They serve as a repair system for the body. There are two main types of stem cells: embryonic stem cells and adult stem cells. Stem cells are divided into two major classes; pluripotent and multipotent. Pluripotent stem cells are replicating cells, which are derived from the embryo or fetal tissues. The pluripotent stem cells facilitate the development of cells and tissues in three primary germ layers such as mesoderm, ectoderm, and endoderm.

The global stem cell therapy market is estimated to be valued at US$ 15,075.5 million in 2022 and is expected to exhibit a CAGR of 21.2% during the forecast period (2022-2030).

Figure 1. Global Stem Cell Therapy Market Share (%), by Cell Source, 2022

Increasing research and development activities for stem cell therapy are expected to boost growth of the stem cell therapy market

Increasing research and development activities by the market players are one of the major factors that are expected to drive growth of the stem cell therapy market over the forecast period. For instance, in July 2018, the Emory Orthopaedics & Spine Center, in collaboration with Sanford Health, Duke University, Andrews Institute, and Georgia Institute of Technology, received US$ 13 million grant from the Marcus Foundation for a multicenter clinical trial studying stem cell options for treating osteoarthritis. The Phase 3 trial was initiated in March 2019 and was expected to complete by December 2021. Moreover, in December 2017, Mayo Clinic initiated the clinical phase I study on safety and feasibility of mesenchymal stem cell therapy in patients with intracerebral hemorrhage. This therapy is used for treating acute spontaneous hemorrhagic stroke.

Stem Cell Therapy Market Report Coverage

Report Coverage	Details
Base Year:	2021	Market Size in 2022:	US$ 15,075.5 Mn
Historical Data for:	2017 to 2020	Forecast Period:	2022 to 2030
Forecast Period 2022 to 2030 CAGR:	21.2%	2030 Value Projection:	US$ 69,982.1 Mn
Geographies covered:	North America: U.S. and Canada Latin America: Brazil, Argentina, Mexico, and Rest of Latin America Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific Middle East: GCC Countries, Israel, and Rest of Middle East Africa: South Africa, North Africa, and Central Africa
Segments covered:	By Cell Source: Adult Stem Cells, Induced Pluripotent Stem Cells, Embryonic Stem Cells, Others By Application: Musculoskeletal Disorders, Wounds and Injuries, Cancer, Autoimmune disorders, Others
Companies covered:	Magellan, Medipost Co., Ltd, Osiris Therapeutics, Inc., Kolon TissueGene, Inc., JCR Pharmaceuticals Co., Ltd., Anterogen Co. Ltd., Pharmicell Co., Inc., and Stemedica Cell Technologies, Inc.
Growth Drivers:	Increasing research and development activities for stem cell therapy Increasing product launches by the key players in the market
Restraints & Challenges:	Limited awareness regarding treatment options The ethical concerns related to embryonic stem cells

Figure 2. Global Stem Cell Therapy Market Share (%), by Region, 2022

Increasing product launches by the key players in the market is expected to drive the global stem cell therapy market over the forecast period.

Increasing launches of new products by the key players in the market is expected to drive the market over the forecast period. For instance, in August 2017, LifeCell, a healthcare service provider, launched an advanced umbilical cord-stem cell collection kit which offers enhanced protection to neonatal stem cells from environmental damage and temperature fluctuations.

Global Stem Cell Therapy Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.

COVID-19 can affect the economy in three main ways: by directly affecting production and demand of drugs, medical devices and nutritional supplements by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, U.A.E., Egypt, and others, are facing problems with regards to the transportation of drugs from one place to another.

However, the COVID-19 pandemic had a negative impact on the global stem cell therapy market, owing to the decrease in research and development for the stem cell therapy. For instance, in October 2021, according to the data published by the National Center for Biotechnology Information, the COVID-19 pandemic has caused significant disruption to the research, manufacturing, clinical development, and market launch of Collaborative Glomerulonephritis Therapy Study for non-COVID-19-related diseases. Additionally, Health technology assessments for non-COVID-19-related topics (including CGTs) will be delayed because faster appraisal for COVID-19-related topics is the first priority. A shortage of supplies of materials for manufacturing, difficulties in clinical trials (e.g., patient recruitment, conduct of placebo-controlled trials, and follow-up), and a delay in regulatory dossier preparation are all contributing factors. Developers of non-COVID-19-related CGTs are also advised to keep close relationships with regulators to report the protocol deviation of clinical trials, and to better understand the possible adaptations in evidence requirements. The disruption of clinical trials will further prejudice the quality of clinical evidence for CGTs, making it even more challenging to achieve a reliable HTA on the treatment benefits and economic impacts of CGTs. The research and development activities for the COVID 19 vaccines were on priority to prevent the spread coronavirus.

Global Stem Cell Therapy Market: Key Developments

In December 2021, Century Therapeutics, Biotechnology Company, collaborated and signed a license agreement with Bristol Myers Squibb, a Pharmaceutical Company, to develop and commercialize up to four induced pluripotent stem cell (“iPSC”) derived, engineered natural killer cell (“iNK”) and / or T cell (“iT”) programs for hematologic malignancies and solid tumors. The first two programs include a program in acute myeloid leukemia and a program in multiple myeloma, which could incorporate either the iNK or a gamma delta iT platform. Bristol Myers Squibb has the option to add two additional programs which can be nominated subject to certain conditions agreed with century in the agreement.

Global Stem Cell Therapy Market: Restraint

The major factors that hinder growth of the global stem cell therapy market include limited awareness regarding treatment options and the ethical concerns related to embryonic stem cells. For instance, according to the data published by the National Center for Biotechnology Information, there is main factor concerning is the fear of the unknown therapy and lack of awareness among the population about the treatment options. Moreover, high cost for the therapies leads to lower adoption leading to reduced demand for the product worldwide.

Furthermore, studies into the therapeutic potential of embryonic stem cells (ESC) are linked to a number of ethical concerns related to the destruction of human embryos. The development of embryo-based stem cell research or therapies may be limited in the future to some part by a lack of appropriate federal policies that define what can be supported in those fields. Federal rules that can aid researchers, scientists, and pharmaceutical companies in developing ESC therapy and facilitating its commercialization are also necessary due to the complexity of the legislation in this field.

Key Players

Major players operating in the global stem cell therapy market include Magellan, Medipost Co., Ltd, Osiris Therapeutics, Inc., Kolon TissueGene, Inc., JCR Pharmaceuticals Co., Ltd., Anterogen Co. Ltd., Pharmicell Co., Inc., and Stemedica Cell Technologies, Inc.

Table of Content

Table of Contents

*Browse 27 market data tables and 29 figures on "Global Stem Cell Therapy Market” - forecast to 2030

Segmentation

Detailed Segmentation:

- Frequently Asked Questions -

What is the current market size and compound annual growth rate (CAGR) of the global stem cell therapy market during the forecast period (2022-2030)?

The global stem cell therapy market size is estimated to be valued at US$ 15,075.5 million in 2022 and is expected to exhibit a CAGR of 21.2% between 2022 and 2030.

What are the major factors driving the market growth?

Factors such as increasing research and development activities for stem cell therapy and increasing product launches by the key players in the market are expected to drive the market growth.

Which is the leading cell source segment in the market?

Adult stem cells is the leading cell source segment in the market.

What are the key factors hampering growth of the global stem cell therapy market?

The major factors hampering growth of the market include limited awareness regarding treatment options and the ethical concerns related to embryonic stem cells.

Which are the major players operating in the market?

Major players operating in the market include Magellan, Medipost Co., Ltd, Osiris Therapeutics, Inc., Kolon TissueGene, Inc., JCR Pharmaceuticals Co., Ltd., Anterogen Co. Ltd., Pharmicell Co., Inc., and Stemedica Cell Technologies, Inc.